Abbott's hepatitis C drug performs well in 2 small trials

04/4/2012 | Wall Street Journal, The

Midstage trials on the drug ABT-450 from Abbott Laboratories showed it helped suppress the hepatitis C virus and achieved a sustained response 24 weeks after treatment ended. ABT-450, which is in the same class as the recently approved HCV drugs Victrelis and Incivek, was given as part of a regimen that included other medications, some of which also are in development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN